Thromb Haemost 1989; 61(01): 007-009
DOI: 10.1055/s-0038-1646517
Original Article
Schattauer GmbH Stuttgart

Effects of Sulfated Polysaccharides on Inhibition of Thrombus Formation initiated by Different Stimuli

J Van Ryn-McKenna
The Department of Pathology, McMaster University Medical Centre and the Canadian Red Cross Blood Transfusion Service, Hamilton, Ontario, Canada
,
E Gray
The Department of Pathology, McMaster University Medical Centre and the Canadian Red Cross Blood Transfusion Service, Hamilton, Ontario, Canada
,
E Weber
The Department of Pathology, McMaster University Medical Centre and the Canadian Red Cross Blood Transfusion Service, Hamilton, Ontario, Canada
,
F A Ofosu
The Department of Pathology, McMaster University Medical Centre and the Canadian Red Cross Blood Transfusion Service, Hamilton, Ontario, Canada
,
M R Buchanan
The Department of Pathology, McMaster University Medical Centre and the Canadian Red Cross Blood Transfusion Service, Hamilton, Ontario, Canada
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 03. Juni 1988

Accepted after revision 31. August 1988

Publikationsdatum:
24. Juli 2018 (online)

Summary

To test the possibility that different doses of heparin or other sulfated polysaccharides are required to inhibit thrombosis initiated by different stimuli, we compared the effects of heparin (HEP), pentosan polysulfate (SP54) and dermatan sulfate (DS) on the inhibition of thrombus formation induced by either I) tissue thromboplastin; II) thrombin; or III) factor Xa. Inhibition of thrombus formation induced by the stimuli was measured in a rabbit jugular vein hypercoagulation/stasis model. First, we determined the minimum dose of each sulfated polysaccharide which inhibited tissue thromboplastin-induced thrombus formation by ∼75%, and then compared the relative effectiveness of this dose to prevent thrombus formation initiated with the other two stimuli. HEP and SP54 were less effective when thrombin was the thrombogenic stimulus, while DS was more effective. HEP was the most effective agent when factor Xa was the stimulus. We conclude that the antithrombotic effectiveness of a given dose of a sulfated polysaccharide may vary depending on the stimulus which initiates thrombus formation.

 
  • References

  • 1 The International Multicentre Trial. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. Lancet 1975; 2: 45-51
  • 2 Kiil J, Kiil J, Axelson F, Andersen D. Prophylaxis against postoperative pulmonary embolism and deep vein thrombosis by low-dose heparin. Lancet 1978; 1: 1115-1116
  • 3 Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1986; 89: 269-359
  • 4 Mannucci PM, Citterio LA, Panajotopoulos N. Low-dose heparin and deep-vein thrombosis after total hip replacement. Thromb Haemostas 1976; 36: 157-164
  • 5 Morris GK, Mitchell JR. Warfarin sodium in the prevention of deep vein thrombosis and pulmonary embolism in patients with fractured neck of femur. Lancet 1976; 2: 869
  • 6 Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of substaneous heparin. Overview of results of randomized trials in general, orthopedic and urologic surgery N Engl J Med 1988; 318: 1162-1173
  • 7 Ofosu FA, Blajchman MA, Modi G, Cerskus A, Hirsh J. Activation of factor X and prothrombin in antithrombin III-depleted plasma. The effects of heparin Thromb Res 1981; 23: 331-345
  • 8 Regoeczi E. Fibrinogen catabolism: Kinetics of catabolism following sudden elevation of the pool with exogenous fibrinogen. Clin Sci 1970; 38: 111-121
  • 9 Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-1245
  • 10 Rosner BA. Fundaments of Biostatistics. P W S Publishers; Boston: 1982. pp 412
  • 11 Ofosu FA, Modi GJ, Hirsh J, Buchanan MR, Blajchman MA. Mechanisms for inhibition of the generation of thrombin activity by sulfated polysaccharides. Ann NY Acad Sci 1987; 485: 41-55
  • 12 Van Ryn-McKenna J, Ofosu FA, Gray E, Hirsh J, Buchanan MR. The effects of dematan sulfate and heparin on inhibition of thrombus growth in vivo. Ann NY Acad Sci. 1988 in press
  • 13 Hemker HC. The mode of action of heparin in plasma. In: Thrombosis and Haemostasis 1987. Verstraete M, Vermylen J, Lijnen R, Amout J. (eds.) Leuven Univ. Press; Leuven: 1987. pp 17-36
  • 14 Gitel SN, Stephenson RC, Wesler S. In vitro and in vivo correlation of clotting protease activity: Effect of heparin. Proc Natl Acad Sci 1977; 74: 3028-3032
  • 15 Walenga JM, Petitou M, Lormeau JC, Samama M, Fareed J, Choay J. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challengers. Thromb Res 1987; 46: 187-198
  • 16 Sie P, Ofosu F, Fernandez F, Buchanan MR, Petitou M, Boneu B. Respective role of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of heparin and of various sulphated polysaccharides. Br J Haematol 1986; 64: 707-714